Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Clinical Oncology 32 (2020) 553–561

Contents lists available at ScienceDirect

Clinical Oncology

journal homepage: www.clinicaloncologyonline.net

Overview

Beyond Performance Status

R. Simcock *, J. Wright †

* Brighton and Sussex University Hospitals NHS Trust, Brighton, UK
† Brighton and Sussex Medical School, Brighton, UK

Received 15 June 2020; received in revised form 19 June 2020; accepted 25 June 2020

Abstract

Oncologists should recognise the need to move beyond the Eastern Cooperative Oncology Group Performance Status (ECOG PS) score. ECOG PS is a longstanding and ubiquitous feature of oncology. It was evolved 40 years ago as an adaption of the 70-year-old Karnofsky performance score. It is short, easily understood and part of the global language of oncology. The wide prevalence of the ECOG PS attests to its proven utility and worth to help triage patient treatment. The ECOG PS is problematic. It is a unidimensional functional score. It is mostly physician assessed, subjective and therefore open to bias. It fails to account for multimorbidity, frailty or cognition. Too often the PS is recorded only once in wilful ignorance of a patient's changing physical state. As modern oncology offers an ever-widening array of therapies that are 'personalised' to tumour genotype, modern oncologists must strive to better define patient phenotype. Using a wider range of scoring and assessment tools, oncologists can identify deficits that may be reversed or steps taken to mitigate detrimental effects of treatment. These tools can function well to identify those patients who would benefit from comprehensive assessment. This overview identifies the strengths of ECOG PS but highlights the weaknesses and where these are supported by other measures. A strong recommendation is made here to move to routine use of the Clinical Frailty Score to start to triage patients and most appropriately design treatments and rehabilitation interventions.

Key words: Comorbidity; frailty; multimorbidity; polypharmacy

Introduction

The safe and effective practice of oncology asks of us that we classify the cancer using appropriate tools. We must then assess the treatment options in the context of the patient's ability to tolerate them. Achieving the optimum therapeutic ratio requires that our patient's fitness meets a threshold. The long-established shorthand for that fitness has been the Eastern Cooperative Oncology Group Performance Status (ECOG PS); a synthesised scale of symptoms and mobility. The ECOG PS has been around for a long time; its development from the 70-year-old Karnofsky performance score (KPS) [1] is summarised in a single paragraph of less than 50 words from a paper written 40 years ago [2], which describes how the percentage-based KPS was further simplified into a five-point scale.

In those intervening decades the ECOG PS has become the common and international language of oncology practice, allowing a swift shorthand that is shared between teams and in research communication.

There is much to recommend the ECOG PS and its impressive longevity attests to a broad utility. The simplicity of a six-point scale has assisted its ubiquity. When compared directly with the KPS (a meta-analysis of studies where healthcare professionals [HCPs] completed both assessments) KPS may perform better [3], although the five-point simplicity of the ECOG PS may be easier for patients to understand and HCPs to remember. That same simplicity contributes to low interobserver variability [4] and agreement between members of the multidisciplinary team [5]. The scale can also be completed by patients themselves with high physician concordance in reporting their functional status [6,7]. In the modern era, ECOG PS recording can also be carried out effectively and accurately with wearable technologies [8].

The ECOG PS has gone on to prove both prognostic and predictive utility. The score has been shown to align closely

Author for correspondence: R. Simcock, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.
E-mail address: richard.simcock@nhs.net (R. Simcock).

https://doi.org/10.1016/j.clon.2020.06.016
0936-6555/

to benefit in the use of cytotoxic chemotherapy in lung cancer [9] and in that context strongly influences treatment decisions in lung cancer chemotherapy [10]. It helps prognostication in a palliative care setting [11] and can predict for depression [12].

The ECOG PS is widely used in UK oncology and in an recent survey 90% of HCPs managing older patients with cancer used it as part of their assessment [13].

The primacy of the ECOG PS is such that it would be rare to see peer-reviewed research in print that did not report the score of treated cohorts. It is also used widely in regulatory frameworks and guidance. In the UK it is used to filter funding for novel cancer therapies. As of March 2020, there are 44 unique drugs (supporting 64 indications for solid tumours) on the NHS England Cancer Drug Fund list. All but two have strictures around the ECOG PS that limit prescribing (three requiring 'sufficient PS', 14 requiring a PS of at least 2 and the remainder needing the patient to demonstrate a PS of 0 or 1). There are no other indicators of fitness required in any of the listings [14]. The Cancer Drug Fund list is dominated by drugs of eye-watering cost and in that context it may be surprising that the only functional assessment required of the patient before prescribing is a five-point scale.

Given this prevalence of the ECOG PS in cancer, a curious aspect is that it has not been more widely adopted outside of oncology, apart from some very limited early uptake in renal and geriatric medicine; as an assessment of function, it has predictive mortality in older adult (non-cancer) inpatients with pneumonia [15].

Problems with Performance Status

Although ECOG PS use is widespread, it is still far from universal. There are still a substantial number of clinicians who will make a decision to use chemotherapy despite a poor PS [10]. The ECOG PS often does not reach the multidisciplinary team meeting where treatment decisions are discussed; in a recent study of UK practice, only 14% of such discussions included information about patient fitness [16]. This may not be a problem with the scale as much as a problem of the team not recognising the need for functional assessment.

Despite the long pedigree of the PS it has significant problems. The useful simplicity of the ECOG PS is also one of its major drawbacks. It lacks granularity, particularly around the (often crucial) decision nexus at PS 2. The score contains no weighting as to whether the impairment in function is musculoskeletal or due to organ dysfunction (e.g. cardiac or respiratory). The PS lacks any dimension to assess the impact of cognition or mood and no heed of patient social status or attitudes. Consider the cases of two men with the same diagnosis and ECOG PS but with widely different physical reserve, functional capability and medical histories (see Table 1). It would not surprise oncology professionals if these two patients had very different experiences with cancer therapy despite having the same ECOG PS score.

Everyday usage of the ECOG PS assumes that the risk–benefit ratio of a given treatment will change according to the points on the scale, with caution required with higher scores due to higher risk. There is a paucity of evidence to support differential outcomes according to ECOG PS and the exclusion of patients of poor PS means that subgroup analysis is usually not possible. When the ECOG PS is reported in clinical trial work it is most often as a clinical feature of the cohorts and occasionally as a variate in terms of benefit; it is only rarely reported as a variate with respect to toxicity. A meta-analysis of over 100 randomised controlled trials showed that although 60% reported PS subgroups for analysis of efficacy none did so for toxicity. This does not help us challenge long held biases, particularly around a ECOG PS threshold of 2 [17].

There are other problems too; the score is (predominantly) physician assessed and therefore subjective and prone to bias [18]. It may vary according to the quality of history taken/provided. Vignette studies have shown that discrepant PS scoring between HCPs was significantly influenced by the provided background social information with these differences most obvious in the decision threshold region around a PS score of 2 [19]. Overestimation of PS is not uncommon and when there is discordance between patient and physician over scoring it associated with poorer prognosis in both solid tumours [7,20,21] and in haematological malignancies [22] Although PS may predict benefit from chemotherapy in a UK lung clinic, physician-assessed PS had poor predictive ability for whether or not a patient would complete planned treatment. In the same study, patient self-rated PS was more usefully predictive [23].

Working with patients to design the best treatment course relates directly to how physicians make decisions. Decision making will be influenced by contextual factors (the environment in which the decision is made), decision maker-related characteristics (the biases and behaviours of the decision maker as a person) and decision-specific elements (the nature of the decision itself) [24]. The impression of a patient's functional status may be formed differently according to context and interpreted differently according to decision maker behaviours. How that functional status assessment is implemented may depend on decision-specific elements. All of these elements are too vulnerable to biases and variation in estimate if we rely on a tool as basic and subjective as the ECOG PS. As we grow our evidence base this too needs to be supported by a greater granularity in understanding treatment effects according to functional status.

There have been attempts to refine and improve the ECOG PS. The Palliative Performance Scale, which includes assessments of self-care, nutritional intake and conscious level [25], shows utility in prognosticating towards the end of life. The Palliative Prognostic Index uses the Palliative Performance Scale, oral intake, dyspnoea at rest and delirium to predict 3-week and 6-week survival. The Palliative Prognostic Score uses clinical prediction of survival, KPS, anorexia, dyspnoea and white cell metrics to

Table 1
Case histories

	Patient 1	Patient 2
	75-year-old males recently diagnosed with lung cancer. Both patients have been short of breath in the months leading to their diagnosis	
Functional status	Independent	Needing help with shopping Recent fall
Comorbidity	Nil significant	Diabetes Hypertension Ischaemic heart disease
Polypharmacy	Takes a statin	5 medications
Nutrition	Body mass index 29	Body mass index 19 Recent weight loss of more 3 kg Loss of appetite
Cognition	No issues	Recently more forgetful
Social status	Attends clinic with wife and daughter	Widower who lives alone
G8 score	16	5
Clinical Frailty Score (Rockwood)	3 (managing well)	6 (moderately frail)
myCARG risk of grade 3–5 toxicity with chemotherapy	59%	86%

Both patients could correctly be assigned a Performance Status of 2 but we would expect their tolerance of the same oncological treatment plan to be very different.

predict 30-day survival in patients with advanced cancers [26]. A further adaptation accounts for delirium [27]. Here the ECOG PS score has mutated in purpose from predicting fitness for treatment to preparedness for the end of life but it is recognised that PS is recorded to a lesser degree once initial treatment has been determined and even less so as a patient progresses through advanced stage of disease into palliative care [28]. In palliative radiotherapy, scores have been developed that use other factors (including site of metastasis, previous radiotherapy, tumour type) added to the ECOG PS or KPS to produce a score that may assist in identifying those most likely to benefit from the treatment (Chow Score) [29,30]. These scores have been adapted because of the limitations of the performance score and all have some proven utility in the specific scenarios for which they have been developed. Adapted performance scores do not help us to fulfil a brief for a tool that provides valuable information across the wider spectrum of all cancer diagnoses, stages and treatments.

Changing Paradigms

When Karnofsky and Burchenal designed their original performance score in 1949, it was as part of a textbook for the nascent science of chemotherapy. Chemotherapy has changed significantly since then and is far from the only therapeutic paradigm in regular usage. Immunotherapy, radiotherapy and surgical oncology trials have all adopted the ECOG PS as a routine baseline assessment. These developing modalities may demand less (or more) of patient fitness. Immunotherapy in particular is a treatment that can appear well tolerated unless toxicities develop. The evolution of toxicity seems to be independent of PS [31]. This has led to critical reviews of the ECOG PS as a triage tool for immunotherapies, particularly in lung cancer, where many patients are assessed as PS 2 or lower at presentation. Meta-analyses of immunotherapy have shown similar overall survival gains regardless of PS [32,33], although they are problematic as they take data from trials that included only small numbers of patients of poor PS [34]. Also, trials of immunotherapy may show similar overall response rate (ORR) benefits regardless of PS, but this may not be enough to overcome the survival disadvantage of poor PS at the outset [35]. There are also signals that despite the overall survival gains in lung cancer immunotherapy appearing to be agnostic of patient PS, this may not be true for all subgroups. This may be particularly the case in older patients, where some outcomes still appear to be driven by poor PS (despite immunotherapy) [36]. These data illustrate that PS does not give us enough information on its own in our current era.

Changing Populations

It is not only treatment options that are evolving; populations are shifting too.

As our populations age and our control of chronic diseases improves, we increasingly deal with the patient with multimorbidities and polypharmacy. Our current systems have evolved around single specialities, which are a poor fit for the patient with multimorbidities. The concept of multispeciality ‘cluster medicine’ [37] has been proposed, but, as yet, oncology seems poorly prepared to adopt this model as training and practice and continue to enshrine specialism over generalism. It is in our current era of the older patient

and the patient with multimorbidity that the ECOG PS is shown to be most deficient.

One important way to move beyond PS is to look instead at frailty. Frailty is a multidimensional concept that will encompass many of the issues that also inform PS. Frailty is variably defined but recognises that an individual may not be able to recover to their functional baseline if physically stressed and is a consequence of a cumulative decline in many physiological systems [38].

It is crucial to understand that multimorbidity, age and frailty are independent; a patient may be older but not frail, have multimorbidities and not be older. Frailty and multimorbidity will overlap [39]. Clinicians will normally intuitively understand that not all older patients are unfit and that ageing and multimorbidity are not universally entwined. What matters is not the enumeration of calendar years or past diagnoses but a focused assessment of fitness. Frailty is likely to be a more helpful term for use by cancer multidisciplinary teams than age as it more specifically focuses on what a patient with cancer is likely to be able to tolerate when receiving treatment.

Beyond Performance Status

PS is a reductive assessment of function but there are multiple ways to enhance this to provide more granular analysis. To tailor therapy most effectively for the potentially frail patient we need to look beyond PS and explore the domains of health characterised in Table 2. We may at the very least ask that the ECOG PS be combined with some other scales of physical performance and ability that would give a less one-dimensional view of the patient's ability and function.

The ECOG PS also gives a 'label' for a patient with no suggestion that there may be room for optimisation or reversibility. To work better, our scores need to identify patients who will benefit from treatment and also identify those who will not, while predicting complications. It should be sensitive enough to be able to detect issues not found by routine history and physical examination in the initial evaluation. It should take account of geriatric syndromes and problems (delirium, falls, pressure ulcers, constipation) as well as smoking, alcohol excess, vision problems, social isolation and loneliness.

Reviews that address polypharmacy with subsequent medical optimisation may well improve functional status – such as optimisation of hypothyroidism or a reduction in opiates.

Frailty is a dynamic state that can improve with intervention; pre-frailty can respond to exercise, calorie review, protein diet and vitamin D supplementation [41]. The simple act of combining a geriatric screening tool, such as the G8, will improve the utility of the PS [42].

One simple triage test would be to use an ECOG PS 2 or higher to trigger the next level of assessment – to focus on the true significance of any deficit to function (and whether there is reversibility). A list of useful tools for each of the domains under consideration is given in Table 2.

Table 2
Domains and how they may be assessed

Functional status	ADLs IADLs MOS physical functioning ECOG Karnofsky Barthel Index PRISMA-7 MOB-T (for fatigue)
Functional status (objective performance)	TUG Gait speed Short physical performance battery Hand grip test Falls history
Psychological health	Geriatric depression score Patient Health Questionnaire PHQ-9 HADS NCCN distress thermometer Mental Health Inventory
Multimorbidity	ACE 27 Charlson Comorbidity Index Klabunde adaptation of the Charlson Comorbidity Index for cancer patients Cumulative Illness Rating Scale
Cognition	MMSE MoCA (more sensitive tool for mild cognitive impairment) [40] Blessed Orientation Memory Concentration Mini-COG Clock drawing test
Polypharmacy	STOP/START
General screening tools	Clinical Frailty Score (Rockwood) G8 VES-13 FACT-G Groningen Frailty Score Senior Adult Oncology Program

ADLs, Activities of Daily Living; ECOG, Eastern Cooperative Oncology Group; FACT-G, Functional Assessment of Cancer Therapy-General; HADS, Hospital Anxiety and Depression Scale; IADLs, Instrumental Activities of Daily Living; Mini-COG, Min-Cog-Screening for Cognitive Impairment in Older Adults; MMSE, Mini Mental State Examination; MOB-T, The MobilityTiredness Scale; MoCA, Montreal Cognitive Assessment; MOS, Medical Outcomes SF-36 Physcial Functioning Scale; NCCN, The National Comprehensive Cancer Network; PRISMA-7, Program of Research to Integrate Services for the Maintenance of Autonomy-7 Scale; STOP, Screening Tool of Older People's Prescriptions; START, Screening Tool to Alert to Right Treatment; TUG, Timed Up and Go; VES-13, Vulnerable Elders Survey.

A significant problem with the ECOG PS is that it does not allow adjustment for functional difficulties that predate the cancer. A careful history of ability to complete the basic

skills of self-care as activities of daily living (ADLs) should be standard. The instrumental activities of daily living (IADLs) are those that are required to maintain independence, e.g. shopping, laundry, paying bills and using the telephone/internet. ADLs/IADLs will broadly correlate with the ECOG PS and share similar characteristics in being able to identify a poorer prognosis [43]. Nonetheless the IADL/ADL history should be an indispensable part of placing the patient in a domestic and societal context. Other functional scores include the Barthel Index. The American Society of Anesthesiologists scale (ASA) used by surgical colleagues gives information that performs similarly well [44], as does the Edmonton Frail Scale, which has been recommended in the elective surgical setting [45].

It is important to acknowledge that for many HCPs, scoring systems are not always popular. Although awareness of scoring systems was relatively high among UK cancer professionals, there has been little enthusiasm to use them [13]. One might speculate that a score is antithetical to a clinician's belief in the 'art' of diagnostic medicine. Whatever the reason for a clinician's dislike of scoring systems, studies that show utility would hopefully become persuasive.

An improvement on performance status scoring would be a scale that would allow for greater granularity than the ECOG PS and would account for cognitive issues.

Physical functioning may be more objectively assessed in the clinic. A comprehensive number of tests are available but the need for a shorthand in clinic has long been recognised. An assessment of function may be carried out in a number of brief physical tasks; these include measures of hand grip strength [46] or gait speed [47]. One in three patients with slow gait speed will be frail. Physical tests can be combined with a brief timed element for greater differential estimations, these include 2-Minute Step Test, 30-Second Sit to Stand, Timed Arm Curl and the Timed Up and Go [48]. All of these tests may be conducted relatively quickly in any normal clinic scenario and (with the exception of grip strength) without specialist equipment. The names of the tests themselves indicate that they can be carried out in seconds or minutes. The ability to have these tests available is not limited by equipment, space or time but by the willingness of the clinical team to accept them as useful. Tests may be combined to increase the range of function tested, e.g. the Short Physical Performance Battery measures a patient's gait speed, balance and timed sit-to-stand; the test has a high predictive power in identifying patients most likely to complete chemotherapy, overall prognosis and physical decline [23,49,50]. Physical functioning may be combined with short functional questions; the PRISMA 7 questionnaire is a simple seven-item questionnaire to identify disability, has been used in earlier frailty studies and is also suitable for postal completion (and may be combined with Timed Up and Go (TUG) or gait speed for improved accuracy) [51].

A review of all the available tools to assess and quantify frailty and its domains is beyond the scope of this article and has been comprehensively carried out by other authors [52–54]. The modern oncologist needs to have insight into these tools and understand when and where they should be effectively deployed in screening their patients.

These tests do not take a long time; validation studies show that screening tests can be completed in less than half an hour, with two thirds of that time spent by the patient or caregiver in completing tests and 5–6 min required by the healthcare provider [55–57]. When we compare this with the amount of time that the patient will spend on diagnostic testing prior to treatment or the costs of that treatment itself, claiming that there is 'no time' to complete functional assessments begins to look indefensible [58]. Baseline echocardiography, Dihydropyrimidine dehydrogenase deficiency testing or renal function assessment may all be part of routine protocol in chemotherapy delivery alongside complex and expensive imaging technology in staging. Adding more detailed functional and frailty assessments should be considered similarly necessary.

For therapies that carry a low burden or for patients who are fit, then the ECOG PS continues to be an adequate basic assessment. In many of these cases, an ECOG PS will tell the treating team enough to know that it is reasonable to proceed with standard of care. Accepting that the PS has a 'green light' function also commits us to accept that it may also point to amber or red and in these situations, a further detailed review is required. That review may take the form of a comprehensive assessment – most often seen in older adults as a Comprehensive Geriatric Assessment (CGA). A CGA is not a score or a number, but a multidisciplinary process that identifies medical, psychosocial and functional limitations of a frail person, which then leads to a co-ordinated plan to maximise potential for health and tackle reversible issues [59,60]. In contrast to the scores described here, a CGA is a process and intervention rather than a simple enumeration of potential issues. A fuller assessment using the domains that are a regular part of a CGA will probably identify issues that are also routinely detected in the PS. For an assessment to have a beneficial purpose it must identify reversible elements of frailty, particularly those that are likely to influence treatment decisions. A CGA therefore becomes a valid use of resources when it may meaningfully influence the oncology decision at hand.

It is not surprising that in such a detailed process an adequate PS may hide problems that can be identified by a CGA [61]. These benefits of a CGA would seem obvious and international guidance for the management of older cancer patients recommends the process as a standard [54,62,63].

In the UK, however, only 15% of oncology HCPs included geriatricians in the care of older patients 'often or always' [13] and with very significant workforce issues greater demand for a CGA may quickly outstrip supply [64]. It is not likely to be possible anytime soon to offer comprehensive assessment for all. Under these circumstances it is reasonable to propose the ECOG PS as permissive for fitter, younger patients and to use more instructive tools and scores to identify and triage those who may benefit from a comprehensive assessment.

When a CGA is not accessible, practical or possible the simple example of adding a G8 to the baseline assessment

still improves prognostic certainty and allows for better and safer triage of patients [65].

PS is an observed scale of function; it was not intended to reflect on patient-reported outcomes. Although PS can correlate with quality of life [66] it was not designed to do so; quality of life measures, however, can, if correctly recorded, give valuable information around function and outcome. When patients use patient-reported outcome measure tools (PROMS) then these can outperform the ECOG PS as a predictor of survival, as can a formal assessment of quality of life [18,67,68]. In older patients, incorporating a patient-reported tool, like the Vulnerable Elders Survey, as part of the early assessment would be helpful (a simple screening tool that can be administered by non-medical personnel in about 4 min in person or over the telephone [69]).

Tools and Calculators

Extra information gathered as part of a comprehensive assessment or as part of a scoring system needs to be more than a proforma version of a thorough history and examination. Oncologists should be persuaded that these data allow for better definition of the patient within the population but moreover assists shared decision making. There are well-validated tools available to oncologists to incorporate features of functional and physical assessment into clinical decision making. The CARG and CRASH tools have been developed to assist higher quality decision making in treating (specifically) older adults. The validation set of the CARG tool was able to predict chemotherapy toxicities for older adults in a way that the KPS was not. The CARG tool has been shown to be practical in application outside of a research setting [70,71]. The models are built to be used in a clinical environment and can enrich a consent procedure and shared decision making with the patient by incorporating personalised information around fitness and frailty [72,73].

Clinical Frailty Score

The Clinical Frailty Score (CFS; developed in Canada by Dr Kenneth Rockwood and team and often named after him) improves on PS [74] but like the ECOG scale broadly relies on the core skills of clinical history taking and examination. The CFS provides greater differentiation than the ECOG PS. It is intended that the CFS be used alongside formal clinical assessment and (ideally) a CGA. It would not be appropriate to define frailty solely on a CFS of 7 or higher without a formal clinical assessment [75]. The CFS is also not validated in patients under the age of 65 years. Although CFS represents an improvement on ECOG PS it should be seen as part of a continuum towards fuller assessment. It is not validated for measuring improvement in individuals after an acute illness, for example. In a perfect world, the CFS may be seen as a conclusion to a patient focused work up including many of the tools described above, triggered by a PS $\geq$ 2. This needs to be done with the aim of improving the patient's current situation or tackling reversible elements of frailty that may permit oncological treatment – in this context, a CGA becomes an oncological geriatric assessment. The CFS was never designed to be an upgrade of the ECOG PS but it certainly has benefits. Perhaps the greatest advantage of the CFS is its widespread use in secondary care. It has been widely adopted throughout acute and emergency medicine in England. The CFS can be used quickly and easily and, as a tool, proven to be useable within 1 min and was acceptable for use by 75% of emergency department staff in a UK study [76]. Because of the utility of the CFS it has been proposed by NHS England as the preferred triage and assessment tool across the National Health Service during the COVID-19 pandemic [77]. The CFS has therefore become a tool for recognising frailty using a language that is shared not just within geriatrics or oncology but throughout the hospital ecosystem. This shared language of frailty already gives the CFS an advantage over the ECOG PS – a codified language only spoken and understood within oncology. Recognition of the utility of the CFS in cancer practice has led to the recommendations in the UK that the score is recorded as part of standard practice in older women with breast cancer and large-scale pilots of CFS triage in lung cancer chemotherapy clinics [78,79].

Conclusions

Clinical teams should understand that incorporating almost any form of fitness assessment is going to build on the reductive scoring of the ECOG PS. This assessment will require time and workforce to implement correctly. Some of these assessments may take several minutes and a battery of assessments may take up to an hour. A few of these assessments (but not all) would prompt further onward referral for a CGA. This should not be positioned as an unreasonable demand as prelude to a treatment that impacts future morbidity and mortality for that patient. We need to move beyond considering these assessments of function and functional reserve as desirable and to accept them as essential.

In an era that promises truly personalised medicine, it is no longer appropriate to assess and record patient fitness for treatment with an overly simplified unidimensional tool such as the ECOG PS. We cannot make claim to be delivering holistic care with such a limited assessment. Modern oncology is asking way too much of the ECOG PS to profile our patients. However, the leap to a full comprehensive (geriatric) assessment is asking way too much of our system, which lacks the time, resources and expertise required.

Moving to record dimensions of frailty, multimorbidity and functional status should become part of standard clinical and research practice. Usages of these tool will allow for better consent processes. This will probably be of greatest utility in those patients of PS 2 and 3 where the scale provides less granular information.

Oncology teams should familiarise themselves with the domains of frailty and how they are scored and assessed. In collaboration with their colleagues in elderly care and prehabilitation and rehabilitation professionals, formalised assessments should be a part of triaged intervention to optimise fitness and to assist the frail.

As clinicians we need to understand what reserve or capacity the patient in front of us has for treatment. Population-based statistics can guide us, but we must also understand that there are no 'magic numbers' or scores. What is required is focused use of the tools described above combined with expert and multidisciplinary judgement.

To manage frailty successfully we need a shared language to be communicated across professional groups and within scientific publication. The CFS has already been embedded across secondary care and shown validity in cancer populations and is recommended here for cancer professionals to adopt more widely.

The CFS provides a means for oncologists to move beyond the limiting confines of the PS, too long solely a measure for cancer, and share language with the rest of the hospital in discussing and measuring frailty. The PS has served us well but a modern paradigm demands more precision in all aspects of our care – especially evaluation of our patients.

We have an obligation to find the best treatment option for individual patients but also to report and record our outcomes accurately. Spending time making fuller assessment of the patient around the domains of multimorbidity, ageing and frailty is time well spent and is minimal in comparison with the time spent by patients on treatment and by teams in managing toxicity.

Conflicts of interest

R. Simcock has received travel assistance and speaker fees from Novartis and has attended paid advisory boards for Exact Science.

References

[1] Karnofksy DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, editor. *Evaluation of chemotherapeutic agents*. New York: Columbia University Press; 1949.

[2] Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, *et al*. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* 1982;5:649–655.

[3] Chow R, Bruera E, Temel JS, Krishnan M, Im J, Lock M. Inter-rater reliability in performance status assessment among healthcare professionals: an updated systematic review and meta-analysis. *Support Care Cancer* 2020;28:2071–2078.

[4] Sorensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. *Br J Canc* 1993;67:773–775.

[5] Zimmermann C, Burman D, Bandukwala S, Seccareccia D, Kaya E, Bryson J, *et al*. Nurse and physician inter-rater agreement of three performance status measures in palliative care outpatients. *Support Care Cancer* 2010;18:609–616.

[6] Martin L, Watanabe S, Fainsinger R, Lau F, Ghosh S, Quan H, *et al*. Prognostic factors in patients with advanced cancer: use of the patient-generated subjective global assessment in survival prediction. *J Clin Oncol* 2010;28:4376–4383.

[7] Blagden SP, Charman SC, Sharples LD, Magee LR, Gilligan D. Performance status score: do patients and their oncologists agree? *Br J Canc* 2003;89:1022–1027.

[8] Gresham G, Hendifar AE, Spiegel B, Neeman E, Tuli R, Rimel BJ, *et al*. Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients. *Dig Med* 2018;1:27.

[9] Pignon J-P, Tribodet H, Scagliotti GV, Douillard J-Y, Shepherd FA, Stephens RJ, *et al*. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. *J Clin Oncol* 2008;26:3552–3559.

[10] Tisnado D, Malin J, Kahn K, Landrum MB, Fletcher R, Klabunde C, *et al*. Variations in oncologist recommendations for chemotherapy for stage IV lung cancer: what is the role of performance status? *J Oncol Pract* 2016;12:653–662.

[11] Jang RW, Caraiscos VB, Swami N, Banerjee S, Mak E, Kaya E, *et al*. Simple prognostic model for patients with advanced cancer based on performance status. *J Oncol Pract* 2014;10:e335–e341.

[12] Miwata K, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, *et al*. Performance status is a risk factor for depression before the diagnosis of lung cancer patients. *Intern Med* 2019;58:915–920.

[13] Kalsi T, Harari D. Assessment methods and services for older people with cancer in the United Kingdom. *World J Clin Oncol* 2020;11:152–161.

[14] NHS England. *Cancer Drugs Fund List* 2020.

[15] Pieralli F, Vannucchi V, De Marzi G, Mancini A, Bacci F, Para O, *et al*. Performance status and in-hospital mortality of elderly patients with community acquired pneumonia. *Intern Emerg Med* 2018;13:501–507.

[16] Cancer Research UK. *Improving the effectiveness of multidisciplinary team meetings in cancer services* 2017.

[17] Cheng S, Qureshi M, Pullenayegum E, Haynes A, Chan KK. Do patients with reduced or excellent performance status derive the same clinical benefit from novel systemic cancer therapies? A systematic review and meta-analysis. *ESMO Open* 2017;2:e000225.

[18] Kerrigan K, Patel SB, Haaland B, Ose D, Weinberg Chalmers A, Haydell T, *et al*. Prognostic significance of patient-reported outcomes in cancer. *JCO Oncol Pract* 2020;16(4):e313–e323. https://doi.org/10.1200/JOP.19.00329.

[19] Datta SS, Ghosal N, Daruvala R, Chakraborty S, Shrimali RK, van Zanten C, *et al*. How do clinicians rate patient's performance status using the ECOG performance scale? A mixed-methods exploration of variability in decision-making in oncology. *Ecancermedicalscience* 2019;13:913.

[20] Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, *et al*. Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. *Br J Canc* 2001;85:1634–1639.

[21] Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M, Li H, *et al*. Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer. *Cancer* 2008;113:2205–2214.

[22] Liu MA, Hshieh T, Condron N, Wadleigh M, Abel GA, Driver JA. Relationship between physician and patient assessment of performance status and survival in a large cohort of patients with haematologic malignancies. *Br J Canc* 2016;115:858–861.

[23] Collins JT, Noble S, Davies HE, Farewell D, Lester JF, Parry D, *et al.* Performance status agreement assessed by the patient and clinician in a rapid access lung cancer service: can either predict completion of treatment? *Eur J Canc Care* 2019;28: e13004.
[24] Glatzer M, Panje CM, Sirén C, Cihoric N, Putora PM. Decision making criteria in oncology. *Oncology* 2018;98(6):370–378.
[25] Anderson F, Downing GM, Hill J, Casorso L, Lerch N. Palliative performance scale (PPS): a new tool. *J Palliat Care* 1996;12: 5–11.
[26] Pirovano M, Maltoni M, Nanni O, Marinari M, Indelli M, Zaninetta G, *et al.* A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. *J Pain Symptom Manage* 1999;17:231–239.
[27] Scarpi E, Maltoni M, Miceli R, Mariani L, Caraceni A, Amadori D, *et al.* Survival prediction for terminally ill cancer patients: revision of the palliative prognostic score with incorporation of delirium. *Oncologist* 2011;16:1793–1799.
[28] Tayjasanant S, Bruera E, Hui D. How far along the disease trajectory? An examination of the time-related patient characteristics in the palliative oncology literature. *Support Care Cancer* 2016;24:3997–4004.
[29] Chow E, Abdolell M, Panzarella T, Harris K, Bezjak A, Warde P, *et al.* Predictive model for survival in patients with advanced cancer. *J Clin Oncol* 2008;26:5863–5869.
[30] Krishnan MS, Epstein-Peterson Z, Chen YH, Tseng YD, Wright AA, Temel JS, *et al.* Predicting life expectancy in patients with metastatic cancer receiving palliative radiotherapy: the TEACHH model. *Cancer* 2014;120:134–141.
[31] Passaro A, Spitaleri G, Gyawali B, Marinis Fd. Immunotherapy in non–small-cell lung cancer patients with performance status 2: clinical decision making with scant evidence. *J Clin Oncol* 2019;37:1863–1867.
[32] Bersanelli M, Brighenti M, Buti S, Barni S, Petrelli F. Patient performance status and cancer immunotherapy efficacy: a meta-analysis. *Med Oncol* 2018;35:132.
[33] Butaney M, Satkunasivam R, Goldberg H, Freedland SJ, Patel SP, Hamid O, *et al.* Analysis of heterogeneity in survival benefit of immunotherapy in oncology according to patient demographics and performance status: a systematic review and meta-analysis of overall survival data. *Am J Clin Oncol* 2019;43(3):193–202.
[34] Friedlaender A, Banna GL, Buffoni L, Addeo A. Poor-performance status assessment of patients with non-small cell lung cancer remains vague and blurred in the immunotherapy era. *Curr Oncol Rep* 2019;21:107.
[35] Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, *et al.* Impact of performance status on treatment outcomes: a real-world study of advanced urothelial cancer treated with checkpoint inhibitors. *Cancer* 2020;126(6): 1208–1216. https://doi.org/10.1002/cncr.32645.
[36] Muchnik E, Loh KP, Strawderman M, Magnuson A, Mohile SG, Estrah V, *et al.* Immune checkpoint inhibitors in real-world treatment of older adults with non–small cell lung cancer. *J Am Geriatr Soc* 2019;67:905–912.
[37] Whitty CJM, MacEwen C, Goddard A, Alderson D, Marshall M, Calderwood C, *et al.* Rising to the challenge of multimorbidity. *BMJ* 2020;368:l6964.
[38] Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. *Lancet* 2013;381:752–762.
[39] Vetrano DL, Palmer K, Marengoni A, Marzetti E, Lattanzio F, Roller-Wirnsberger R, *et al.* Frailty and multimorbidity: a systematic review and meta-analysis. *J Gerontol A Biol Sci Med Sci* 2019;74:659–666.
[40] Rambeau A, Beauplet B, Laviec H, Licaj I, Leconte A, Chatel C, *et al.* Prospective comparison of the Montreal Cognitive Assessment (MoCA) and the Mini Mental State Examination (MMSE) in geriatric oncology. *J Geriatr Oncol* 2019;10: 235–240.
[41] Travers J, Romero-Ortuno R, Bailey J, Cooney M-T. Delaying and reversing frailty: a systematic review of primary care interventions. *Br J Gen Pract* 2019;69:e61–e69.
[42] Takahashi M, Takahashi M, Komine K, Yamada H, Kasahara Y, Chikamatsu S, *et al.* The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: a retrospective, single institutional study. *PLoS One* 2017;12:e0179694.
[43] Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F, Barbera S, *et al.* Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. *J Clin Oncol* 2005;23: 6865–6872.
[44] Young J, Badgery-Parker T, Dobbins T, Jorgensen M, Gibbs P, Faragher I, *et al.* Comparison of ECOG/WHO performance status and ASA score as a measure of functional status. *J Pain Symptom Manage* 2015;49:258–264.
[45] Dhesi JK, Lees NP, Partridge JSL. Frailty in the perioperative setting. *Clin Med* 2019;19:485.
[46] Burtin C, Bezuidenhout J, Sanders KJC, Dingemans AC, Schols A, Peeters STH, *et al.* Handgrip weakness, low fat-free mass, and overall survival in non-small cell lung cancer treated with curative-intent radiotherapy. *J Cachexia Sarcopenia Muscle* 2020;11(2):370–378.
[47] Brown JC, Harhay MO, Harhay MN. Patient-reported versus objectively-measured physical function and mortality risk among cancer survivors. *J Geriatr Oncol* 2016;7:108–115.
[48] Quinn SE, Crandell CE, Blake ME, Bontrager AM, Dempsey AG, Lewis DJ, *et al.* The correlative strength of objective physical assessment against the ECOG performance status assessment in individuals diagnosed with cancer. *Phys Ther* 2020;100: 416–428.
[49] Brown JC, Harhay MO, Harhay MN. Physical function as a prognostic biomarker among cancer survivors. *Br J Canc* 2015; 112:194–198.
[50] Owusu C, Margevicius S, Schluchter M, Koroukian SM, Berger NA. Short physical performance battery, usual gait speed, grip strength and vulnerable elders survey each predict functional decline among older women with breast cancer. *J Geriatr Oncol* 2017;8:356–362.
[51] Raîche M, Hébert R, Dubois MF. PRISMA-7: a case-finding tool to identify older adults with moderate to severe disabilities. *Arch Gerontol Geriatr* 2008;47:9–18.
[52] Kelly CM, Shahrokni A. Moving beyond Karnofsky and ECOG Performance Status assessments with new technologies. *J Oncol* 2016;2016:6186543.
[53] Cohen C, Reuben D, Naeim A. Assessing the older cancer patient. In: Hurria A, Balducci L, editors. *Geriatric oncology*. New York: Springer; 2009. p. 17–45.
[54] Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen MLG, Extermann M, *et al.* International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. *J Clin Oncol* 2014;32:2595–2603.
[55] Hurria A, Gupta S, Zauderer M, Zuckerman EL, Cohen HJ, Muss H, *et al.* Developing a cancer-specific geriatric assessment: a feasibility study. *Cancer* 2005;104:1998–2005.
[56] Hurria A, Akiba C, Kim J, Mitani D, Loscalzo M, Katheria V, *et al.* Reliability, validity, and feasibility of a computer-based

geriatric assessment for older adults with cancer. *J Oncol Pract* 2016;12:e1025–e1034.
[57] Williams GR, Deal AM, Jolly TA, Alston SM, Gordon BB, Dixon SA, *et al*. Feasibility of geriatric assessment in community oncology clinics. *J Geriatr Oncol* 2014;5:245–251.
[58] Hamaker ME, Wildes TM, Rostoft S. Time to stop saying geriatric assessment is too time consuming. *J Clin Oncol* 2017; 35:2871–2874.
[59] Devons CA. Comprehensive geriatric assessment: making the most of the aging years. *Curr Opin Clin Nutr Metab Care* 2002; 5:19–24.
[60] Stuck AE, Siu AL, Wieland GD, Adams J, Rubenstein LZ. Comprehensive geriatric assessment: a meta-analysis of controlled trials. *Lancet* 1993;342:1032–1036.
[61] Jolly TA, Deal AM, Nyrop KA, Williams GR, Pergolotti M, Wood WA, *et al*. Geriatric assessment-identified deficits in older cancer patients with normal performance status. *Oncologist* 2015;20:379–385.
[62] Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, *et al*. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology. *J Clin Oncol* 2018;36: 2326–2347.
[63] Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S, *et al*. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). *Crit Rev Oncol Hematol* 2005;55: 241–252.
[64] Bridges J, Simcock R. Meeting the workforce challenges for older people living with cancer. *Int J Nurs Stud* 2017;65: A1–A2.
[65] Chakiba C, Bellera C, Etchepare F, Mathoulin-Pelissier S, Rainfray M, Soubeyran P. The prognostic value of G8 for functional decline. *J Geriatr Oncol* 2019;10:921–925.
[66] Moningi S, Walker AJ, Hsu CC, Reese JB, Wang J-Y, Fan KY, *et al*. Correlation of clinical stage and performance status with quality of life in patients seen in a pancreas multidisciplinary clinic. *J Oncol Pract* 2015;11:e216–e221.
[67] Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. *J Clin Oncol* 2008;26:1355–1363.
[68] Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. *Health Qual Life Outcome.* 2009;7:102.
[69] Min L, Yoon W, Mariano J, Wenger NS, Elliott MN, Kamberg C, *et al*. The vulnerable elders-13 survey predicts 5-year functional decline and mortality outcomes in older ambulatory care patients. *J Am Geriatr Soc* 2009;57:2070–2076.
[70] Mariano C, Jamal R, Bains P, Hejazi S, Chao L, Wan J, *et al*. Utility of a chemotherapy toxicity prediction tool for older patients in a community setting. *Curr Oncol* 2019;26:234–239.
[71] Alibhai SMH, Breunis H, Gregg RW, Hansen AR, Warde PR, Timilshina N, *et al*. Validating the Cancer and Aging Research Group (CARG) toxicity prediction tool in older men receiving chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) and extending it to androgen receptor targeted agents. *J Clin Oncol* 2019;37:11510.
[72] Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, *et al*. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. *J Clin Oncol* 2011;29: 3457–3465.
[73] Hurria A, Mohile S, Gajra A, Klepin HD, Muss HB, Chapman A, *et al*. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. *J Clin Oncol* 2016;34:2366–2371.
[74] Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, *et al*. A global clinical measure of fitness and frailty in elderly people. *CMAJ* 2005;173:489–495.
[75] British Geriatric Society. *Fit for frailty: consensus best practice guidance for the care of older people living in community and outpatient settings*. British Geriatric Society; 2014.
[76] Elliott A, Phelps K, Regen E, Conroy SP. Identifying frailty in the emergency department – feasibility study. *Age Ageing* 2017;46:840–845.
[77] National Institute for Health and Care Excellence. *COVID-19 rapid guideline: critical care in adults NG159* 2020.
[78] Gomes F, Baker K, Woods J, Bruce J, Eaton M, Higham P, *et al*. MA19.09 Assessing clinical frailty in advanced lung cancer patients - an opportunity to improve patient outcomes? *J Thorac Oncol* 2019;14:S329.
[79] Annual Report. Available at:*National Audit of Breast Cancer in Older Patients* 2019 https://www.nabcop.org.uk/reports/nabcop-2019-annual-report/2019.